Target Health
Aliath Bioventures aims to impact patients’ lives and healthcare systems working with entrepreneurs to create new healthcare solutions developed by sustainable companies.
Aliath is a life sciences venture capital investor and an investment advisor to AltamarCAM specialized in the life sciences and healthcare markets. Our team advises AltamarCAM on the life sciences investment strategy and its execution, by sourcing, structuring, and developing investments.
Inspired by our mission and driven by experience, talent, and alignment.
Our team is formed of industry veterans and investment experts with extensive knowledge of the healthcare ecosystem, complementary backgrounds, and proven professional track record. We invest alongside the funds´ investors and our carry is aligned with our impact goals.
Turn Healthcare challenges into business opportunities.
We seek companies built on disruptive trends that are providing an opportunity to address unmet medical needs and the sustainability of healthcare systems.
Innovation, Intention and Impact.
Aliath Bioventures aims to provide solutions to the most pressing healthcare challenges of our times by targeting therapeutics and health technology companies, from seed to late stage. We follow our 3-i framework (innovation, intention, impact) and apply impact principles and standards.
Build better companies.
We target sustainable and competitive companies. The primary goal of ACP Aliath Bioventures II is to achieve competitive financial returns developing sustainable companies. We design protocols to help portfolio companies be sustainable and work hand in hand with their management to improve their sustainability.
deepull unveils 1 hour, direct-from-blood multiplex PCR test for 95% of sepsis-causing pathogens at ESCMID 2024
deepull, a medical diagnostics company developing culture-free diagnostic solutions for rapid pathogen identification in
Peptomyc Appoints Selwyn Ho to its Board of Directors
Peptomyc S.L., a clinical stage company specialized in the development of protein therapeutics targeting
MYC targeting by OMO-103 in solid tumors: a phase 1 trial
Peptomyc presents results of their Ph1 study of OMO-103 in advanced solid tumours. OMO-103
Peptomyc’s first MYC inhibitor, OMO-103, demonstrates safety and anti-tumor activity in a phase I clinical trial
Peptomyc is proud to announce that the results of the MYCure clinical trial have
binx health Enters into National Distribution Agreement with Cardinal Health to Increase Access to the CLIA-waived, FDA-cleared binx io
binx health, a healthcare technology and diagnostics company focused on expanding Sexually Transmitted Infection
binx health Expands Nationwide Distribution of the binx io Molecular Point-of-Care Platform
binx health announced today it has entered into a non-exclusive national distribution agreement with
